Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: A clinical-stage medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The lead product, NB1, is currently in a pilot clinical study in Australia. The company has no significant operating history and has not generated revenue.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(765,988) | $(1,017,092) |
| Loss Per Share (Basic & Diluted) | $(0.43) | $(1.92) |
| Cash and Cash Equivalents (End of Period) | $4,530,040 | $2,746,555 |
| Net Cash Used in Operating Activities | $(804,282) | $(926,125) |
| Total Assets | $4,979,305 | $5,796,135 |
| Total Liabilities | $309,386 | $418,587 |
| Stockholders' Equity | $4,669,919 | $5,377,548 |
Debt and Liquidity: The company has no long-term debt. Total current liabilities are $309,386, primarily consisting of accounts payable and accrued expenses. The company holds $4.1 million in a flexible CD account at Bank of America.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 24.7% to $0.77 million from $1.02 million in Q1 2025.
- Operating Expenses: Total operating expenses declined 22.5% to $805,054.
- R&D Expenses: Decreased significantly by 66.6% to $141,597, attributed to the timing of clinical trial activities.
- G&A Expenses: Increased by 7.9% to $663,457.
- Interest Income: Increased 93.6% to $38,801 due to higher interest rates on cash balances.
- Financing Activity: No shares were sold under the At-The-Market (ATM) facility in Q1 2026, compared to net proceeds of $347,549 in Q1 2025.
Outlook, Risks, and Management Commentary
Going Concern: The company has incurred an accumulated deficit of approximately $88.9 million since inception. Management estimates operating expenditures for the next twelve months at $5.4 million. While current cash ($4.5 million) is expected to fund operations into the fourth quarter of 2026, the filing states that these factors raise substantial doubt about the company's ability to continue as a going concern. The independent auditors also expressed substantial doubt in the 2025 annual report.
Capital Needs: The company intends to raise additional debt or equity financing. Failure to secure funding may require scaling back or discontinuing product development programs.
Risks and Contingencies:
- Regulatory Approval: Success depends on FDA approval for the NELL-1/DBM combination product (PMA application required).
- Clinical Trials: Risks include delays or suspension of the pilot clinical study in Australia.
- Licensing Obligations: The company holds an exclusive license from UCLA TDG with significant milestone payments (e.g., $100,000 for feasibility study enrollment, $250,000 for pivotal study, up to $8 million diligence fee upon commercial sale).
- Warrant Liability: A liability of $438 exists for warrants classified under ASC 815, subject to fair value remeasurement.
Investor Verification Checklist
- Cash Runway: Verify if the $4.5 million cash balance is sufficient to reach the pivotal trial phase or if immediate fundraising is required before Q4 2026.
- Clinical Trial Status: Confirm the enrollment progress and safety data from the NB1 pilot study in Australia.
- Financing Terms: Assess the potential dilution or restrictive covenants associated with future equity or debt financing.
- UCLA Milestones: Review the specific triggers for the remaining milestone payments to UCLA TDG and the company's ability to meet them.
- Warrant Liability: Monitor the fair value of the warrant liability, as volatility changes could impact reported net income/loss.